Monitoring response to transarterial chemoembolization in hepatocellular carcinoma using 18F-Fluorothymidine Positron Emission Tomography
Autor: | Aboagye, E, Sharma, R, Inglese, M, Dubash, S, Lu, H, Pinato, D, Patel, N, Chung, A, Sanghera, C, Tait, A, Mauri, F, Crum, W, Barwick, T |
---|---|
Přispěvatelé: | Medical Research Council (MRC) |
Rok vydání: | 2020 |
Předmět: |
CELLULAR PROLIFERATION
Science & Technology response Radiology Nuclear Medicine & Medical Imaging KINETIC-ANALYSIS DIFFERENTIATING TUMOR 1103 Clinical Sciences CHEMOTHERAPY VALIDATION F-18-FDG Nuclear Medicine & Medical Imaging hepatocellular cancer POSITRON-EMISSION-TOMOGRAPHY MARKER C-11-ACETATE PET/CT BREAST-CANCER 18F-FLT PET Life Sciences & Biomedicine F-18-FLT PET |
Popis: | Accurate disease monitoring is essential following transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) due to potential for profound adverse event and large variation in survival outcome. Post-treatment changes on conventional imaging can confound determination of residual/recurrent disease, magnifying the clinical challenge. Based on increased expression of thymidylate synthase (TYMS), thymidine kinase-1 (TK-1) and SLC29A1 (Equilibrative nucleoside transporter 1, ENT1) in HCC compared with liver tissue, we conducted a proof of concept study evaluating the efficacy of 18F-fluorothymidine (18F-FLT)-PET to assess response to TACE. As previous PET studies in HCC have been hampered by high background liver signal, we investigated if a temporal-intensity voxel-clustering (“Kinetic Spatial Filtering”) (KSF) improved lesion detection. Methods: A tissue microarray (TMA) was built from 36 HCC samples and matched surrounding cirrhotic tissue and was stained for thymidine kinase-1 (TK-1). A prospective study was conducted; eighteen patients with a diagnosis of HCC by American Association for the Study of Liver Diseases criteria (AALSD) who were eligible to treatment with TACE were enrolled. Patients underwent baseline conventional imaging and dynamic 18F-FLT-PET/KSF followed by TACE. Repeat imaging was performed 6-8 weeks post TACE. PET parameters were compared with modified-Response Evaluation in Solid Tumours (mRECIST) enhancement-based criteria. Results: Cancer Genome Atlas analysis revealed increased RNA expression of TYMS, TK-1 and SLC29A1 in HCC. TK-1 protein expression was significantly higher in HCC (p |
Databáze: | OpenAIRE |
Externí odkaz: |